TARGT Gene Therapy Platform for Correction of Anemia in End-Stage Renal Disease Academic Article uri icon


  • A new protein-delivery platform can provide sustained secretion of recombinant human erythropoietin with the use of small, transduced autologous dermal implants. Study patients with end-stage renal disease were found to have maintenance of stable hemoglobin levels.

publication date

  • January 1, 2017